Editorial Coverage: Smoking is the leading cause of preventable
death in the world today. Globally, 7 million people die every year
from tobacco use, and the number is projected to increase to 8
million if the pattern of smoking doesn’t change. These disturbing
statistics are being noted by companies with experience and
interest in working to make a difference in the world and provide
effective ways to support and help smokers quit. One of those
companies, Kaival Brands Innovations Group Inc. (OTCQB:
Profile), recently announced it had
acquired a patent for a synthetic nicotine and synthetic nicotine
addiction therapy products; the company is also creating a lab,,
which will manufacture and distribute products developed from that
patent. Kaival isn’t the only company with that objective in mind.
Since 2008, Philip
Morris International Inc. (NYSE: PM) has invested
more than $7.2 billion in the science and research of developing
smoke-free products. Imperial
Brands (OTCQX: IMBBY) is in the process of
developing a range of Next Generation Products with the potential
to reduce smoking-related disease. Earlier this year, Johnson
& Johnson (NYSE: JNJ) released Nicorette(R)
Mouth Spray. And Cigna
Corporation (NYSE: CI) has created a Quit Smoking
online campaign that provides extensive information and resources
for individuals trying to kick the habit.
- Smoking is the leading cause of preventable death in the world,
with seven million people dying annually from tobacco use.
- Kaival Brands has acquired a patent for a formulation of
purified synthetic nicotine that is tobacco free.
- Kaival Labs Inc., a wholly owned subsidiary of KAVL, has been
created to develop products associated with that exclusive
Click here to view
the custom infographic of the Kaival Brands Innovations Group Inc.
(OTCQB: KAVL) editorial.
Living with Death, Disease
The Centers for Disease Control and Prevention reports that
approximately 1,300 people die
every day as a result of smoking. In addition, more than 16
million Americans are living with a disease caused by smoking.
Smoking and tobacco have been linked to diseases and disabilities
that impact nearly every organ of the body, including cancer, heart
disease, stroke, lung disease, diabetes, chronic obstructive
pulmonary disease, and more.
And all of this can be prevented.
The fact that millions of deaths could be prevented if the right
products and support were available has not gone unnoticed. Savvy
companies recognize the potential benefits of providing solutions
in this space may include more than saving lives. According to a
2019 Global Smoking Cessation Market Analysis, the smoking
cessation market is projected to reach $63.99 billion by 2026 and
grow at a CAGR of 16.9% during 2018 to 2026.
An Exclusive Patent
Even with the threat of death and disease, 34.2 million U.S. adults still smoke, according
to the latest numbers from the National Health Information Survey.
However, the vast majority of them — an estimated 70% of current
adult smokers in the country — want to quit; in fact, 55% have
attempted to quit in the past year. Unfortunately, only 7% are able
to kick the habit because nicotine is such a highly addictive
chemical, and cigarettes deliver the ingredient so rapidly.
Innovations Group Inc. (OTCQB: KAVL), a company focused on
growing and incubating innovative and profitable products into
mature, dominant brands, recognizes the need to make a difference
in the smoking cessation sector. The company, which has reported
$54.8 million in
revenue and $6.9 million in gross profits thus far this year,
recently obtained an international patent portfolio concerning full
customization of certain isomeric properties of synthetic nicotine.
This Tobacco-Free Nicotine ("TFN") contains no trace of tobacco;
rather it is made from a natural starter that undergoes a series of
chemical reactions to produce the final TFN product.
"The science behind these patents has discovered that within the
nicotine molecule, the S-isomers control the addictive properties,
whereas the R-isomers control the beneficial qualities of the
nicotine that a user enjoys,” explained Kaival Brands CEO Niraj
Patel. “The exclusivity is that the patents allows us to control
the specific ratios of each isomer in the final synthetic nicotine
molecule we produce for cessation products. We can now create
completely unique products for smoking cessation and nicotine
addiction therapy that remain effective and satisfying for the
user, but are free from nicotine’s addictive traits.”
Eradication of Nicotine Addiction
In conjunction with the patent, Kaival Brands has announced the
creation of Kaival Labs
Inc., a wholly owned subsidiary, that will own the patent and
develop associated products.
“Kaival Labs will own the patented science to create a pure, yet
non-addictive synthetic nicotine for the development and production
of smoking cessation and nicotine replacement therapy products,”
said Patel. “Tobacco-Free Nicotine ('TFN') is a certified clean,
pure, non-tobacco-derived synthetic nicotine, and a key ingredient
in numerous products like nicotine patches, lozenges, gums, vape
sticks, e-liquids and more.”
Kaival Labs is focused on pioneering the movement in creating a
tobacco-free future. The new facility will rely on research and
science to formulate and design smoking cessation treatment options
to support and assist millions of people in their efforts to quit
smoking. The lab is also intent on improving public health through
the gradual eradication of nicotine addiction.
True Step-Down Products
Most of the smoking cessation products or Nicotine Reduction
Therapy ("NRT") products currently available are generally
ineffective. The majority of them are designed to simply decrease
the concentrations of nicotine, calling for users themselves to
reduce their usage over time.
Kaival Labs’ newly acquired patent provides the ability to
control the levels of each isomer in a final product, thereby
producing patented, true step-down products that reduce nicotine
addiction levels without reducing the benefits a user is used to.
The R-S- isomeric ratio in nicotine accounts for the addictive and
beneficial properties and strengths of the chemical. Kaival Labs’
exclusive NRT formulation modifies the ratio of R- S- isomers,
resulting in synthetic nicotine that is effective in curbing
nicotine addiction and may even have potential for use on a medical
level in most beneficial form.
“Billions of smokers and tobacco users worldwide are looking for
an answer and a real solution to their nicotine addiction
problems,” said Patel. “Imagine patent-protected products, either
approved pharmaceutically or made available over-the-counter, that
offered a way to truly ease a user off their addictive cravings for
nicotine without losing any of their accustomed benefits along the
way. We are excited to develop these innovative patents and bring
effective, enjoyable smoking cessation products to market, helping
all nicotine users lead healthier and higher-quality lives.”
In a space where desperate smokers are seeking solutions, Kaival
Brands appears to be particularly well positioned to take advantage
of the huge potential and see substantial growth.
Supporting Efforts to Quit
Of course, Kaival Brands isn’t the only company working in the
sector. Given the tremendous potential, companies with interest and
experience in smoking cessation are working to capture market share
and offer support to smokers who yearn to quit.
Morris International Inc. (NYSE: PM) has shared
is to offer current adult smokers a better choice than
continued smoking. In efforts to transform that vision into
reality, the company has invested approximately $7.2 billion into
the science and research of developing smoke-free products. PM also
employs more than 400 world-class scientists, engineers and
technicians in the development of a portfolio of smoke-free
products that deliver nicotine without burning tobacco.
Brands (OTCQX: IMBBY) is committed in its efforts to
smokers from combustible tobacco products to potentially
less-harmful alternatives. Those efforts include the
development of Next Generation Products that have the potential to
reduce smoking-related disease, including its presence in the
vaping industry. IMBBY’s pioneer vaping brand, blu, includes vapor
products that are battery-powered devices that heat e-liquids to
create a vapor that is inhaled by the user. These products are
fundamentally different from all tobacco-based products and devices
as they do not contain tobacco leaf.
& Johnson (NYSE: JNJ) is involved in
Nicorette innovation with the release of its new Nicorette(R)
Mouth Spray, which is designed for rapid relief of nicotine
cravings. Product information notes that anyone wanting to quit
smoking may have to struggle with withdrawal symptoms. With two
sprays into the mouth, Nicorette Spray offers rapid and effective
help to relieve acute nicotine cravings within a minute. Based on
the company’s research, smokers who use Nicorette Mouth Spray are
twice as likely to get through 12 months without a cigarette.
Corporation (NYSE: CI) has gathered extensive
information as well as resources in its online smoking
cessation campaign. The campaign outlines the components of
effective smoking cessation programs, provides strategies for
quitting smoking and staying smoke-free, and offers specific steps
for undertaking efforts to quit smoking. In addition, the campaign
suggests places to go for support and provides insightful
information into why smoking is addictive and what the challenges
and benefits may be for those desiring to quit.
All these companies share the same end game: to save lives and
decrease disease-related disabilities related smoking and tobacco
use. Their commitment to providing effective products and solutions
in the smoking cessation sector could make a significant difference
in efforts to reduce the numbers and provide hope to smokers who
are desperately seeking to live healthier lives.
For more information about Kaival Brands, please visit Kaival Brands
Innovations Group Inc. (OTCQB: KAVL).
(“NNW”) is a financial news and content distribution company, one
of 40+ brands within the InvestorBrandNetwork (“IBN”), that
provides: (1) access to a network of wire
solutions via NetworkWire to
reach all target markets, industries and demographics in the most
effective manner possible; (2) article and
editorial syndication to 5,000+ news outlets; (3)
enhanced press release solutions to ensure maximum
impact; (4) social media distribution via IBN
millions of social media followers; and (5) a full
array of corporate communications solutions. As a multifaceted
organization with an extensive team of contributing journalists and
writers, NNW is uniquely positioned to best serve private and
public companies that desire to reach a wide audience comprising
investors, consumers, journalists and the general public. By
cutting through the overload of information in today’s market, NNW
brings its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text
“STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
New York, New York
NetworkNewsWire is part of the InvestorBrandNetwork
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW is a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertakes no
obligation to update such statements.
New York, New York